Vliyanie metformina na provospalitel'nyei prokoagulyantnye narusheniya u patsientokv postmenopauze s metabolicheskim sindromom
https://doi.org/10.14341/2071-8713-4951
Abstract
The aim of the study was to assess the effect of metformin plus lifestyle modification on procoagulant and proinflammatory state
associated with metabolic syndrome in postmenopausal women. Materials and methods: The 12-month prospective, open, randomized
study included 58 postmenopausal women (age 55 [53; 56]; postmenopause 5 [4; 8] years) with metabolic syndrome (IDF, 2005).
Participants were randomized into two groups receiving either metformin (1 g per day) plus lifestyle modification (n=29), or lifestyle
modification alone (control group) (n=29). Blood tests were performed before and after the treatment period to evaluate parameters
of coagulant and anticoagulant blood systems: prothrombin index, activated partial tromboplastin time (APTT), thrombin time, activities
of factors VII (FVII),VIII (FVIII), von Willebrand factor (vWF), antithrombin III, plasminogen activator inhibitor-1 (PAI-1),
tissue-type plasminogen activator (t-PA) and screening test for the protein C pathway. Also we assessed fibrinogen, C-reactive protein
(CRP) and adiponectin concentrations. Results: After one year of treatment in metformin group CRP level decreased significantly
from 4,98 [2,72; 11,95] to 2,56 [1,92; 6,76] mg/l (р<0,0001), fibronolysis improved (PAI-1 activity decreased from 21,1 [8,86; 33,59]
to 9,5 [4,69; 16,14] U/ml (p=0,0005)) and adiponectin level increased from 10,89 [6,84; 16,78] to 14,36 [7,71; 17,4] mcg/ml (р=0,0013).
All these changes were independent from improvements in insulin sensitivity (HOMA-IR reduction) as a result of metformin use.
Also we observed moderate decreases in FVII activity, fibrinogen concentration and increase in protein C anticoagulant pathway,
but these changes were not significant. In control group there were no any significant changes in observable parameters. Conclusion:
Metformin plus lifestyle modification, in contrast to lifestyle modification alone, resulted in improvements of proinflammatory state
(CRP and adiponectin levels) and impaired fibrinolysis (decreased PAI-1 activity), associated with metabolic syndrome.
associated with metabolic syndrome in postmenopausal women. Materials and methods: The 12-month prospective, open, randomized
study included 58 postmenopausal women (age 55 [53; 56]; postmenopause 5 [4; 8] years) with metabolic syndrome (IDF, 2005).
Participants were randomized into two groups receiving either metformin (1 g per day) plus lifestyle modification (n=29), or lifestyle
modification alone (control group) (n=29). Blood tests were performed before and after the treatment period to evaluate parameters
of coagulant and anticoagulant blood systems: prothrombin index, activated partial tromboplastin time (APTT), thrombin time, activities
of factors VII (FVII),VIII (FVIII), von Willebrand factor (vWF), antithrombin III, plasminogen activator inhibitor-1 (PAI-1),
tissue-type plasminogen activator (t-PA) and screening test for the protein C pathway. Also we assessed fibrinogen, C-reactive protein
(CRP) and adiponectin concentrations. Results: After one year of treatment in metformin group CRP level decreased significantly
from 4,98 [2,72; 11,95] to 2,56 [1,92; 6,76] mg/l (р<0,0001), fibronolysis improved (PAI-1 activity decreased from 21,1 [8,86; 33,59]
to 9,5 [4,69; 16,14] U/ml (p=0,0005)) and adiponectin level increased from 10,89 [6,84; 16,78] to 14,36 [7,71; 17,4] mcg/ml (р=0,0013).
All these changes were independent from improvements in insulin sensitivity (HOMA-IR reduction) as a result of metformin use.
Also we observed moderate decreases in FVII activity, fibrinogen concentration and increase in protein C anticoagulant pathway,
but these changes were not significant. In control group there were no any significant changes in observable parameters. Conclusion:
Metformin plus lifestyle modification, in contrast to lifestyle modification alone, resulted in improvements of proinflammatory state
(CRP and adiponectin levels) and impaired fibrinolysis (decreased PAI-1 activity), associated with metabolic syndrome.
References
1. Аметов А.С., Кондратьева Л.В. Метформин - основа терапии пациентов с метаболическим синдромом // РМЖ. - 2006. - Т. 14 (26): 1905-11.
2. Берковская М.А., Бутрова С.А. Распространенность нарушений свертывающей и противосвертывающей систем крови у женщин с метаболическим синдромом в постменопаузе // Ожирение и метаболизм. - 2010. - № 3(24): 21-7.
3. Дедов И.И., Бутрова С.А., Дзгоева Ф.X. Динамика факторов риска сахарного диабета 2 типа и сердечно-сосудистых заболеваний у больных с абдоминальным типом ожирения // Ожирение и метаболизм. - 2004. - № 2. - Р. 19-24.
4. Adamia N., Virsaladze D., Charkviani N., Skhirtladze M., Khutsishvili M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes // Georgian Med News. - 2007. - № (145). - Р. 52-5.
5. Bahia L., Aguiar L.G., Villela N., Bottino D., Godoy-Matos A.F., Geloneze B., Tambascia M., Bouskela E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome // Clinics. - 2006. - № 61(5). - Р. 433-40.
6. Bos M.B., de Vries J.H., Wolffenbuttel B.H., Verhagen H., Hillege J.L., Feskens E.J. [The prevalence of the metabolic syndrome in the Netherlands: increased risk of cardiovascular diseases and diabetes mellitus type 2 in one quarter of persons under 60] // Ned Tijdschr Geneeskd. - 2007. - № 151(43). - Р. 2382-8.
7. Bulcao C., Ribeiro-Filho F.F., Sañudo A., Roberta Ferreira S.G. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome // Am J Cardiovasc Drugs. - 2007. - № 7(3). - Р. 219-24.
8. Charles M.A., Morange P., Eschwège E., André P., Vague P., Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity // Diabetes Care. - 1998. - № 21(11). - Р. 1967-72.
9. Chu M.C., Cushman M., Solomon R., Lobo R.A. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers // Am J Obstet Gynecol. - 2008. - № 199(5). - Р. 526-7.
10. Dentali F., Romualdi E., Ageno W. The metabolic syndrome and the risk of thrombosis // Haematologica. - 2007. - № 92(3). - Р. 297-9.
11. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifesyill intervention or metformin // N Engl J Med. - 2002. - № 346, 393-403.
12. Eguchi K., Tomizawa H., Ishikawa J., Hoshide S., Numao T., Fukuda T., Shimada K., Kario K. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes // Hypertens Res. - 2007. - № 30(1). - Р. 23-30.
13. Eriksson A., Attvall S., Bonnier M., Eriksson J.W., Rosander B., Karlsson F.A. Short-term effects of metformin in type 2 diabetes // Diabetes Obes Metab. - 2007. - № 9(4). - Р. 483-9.
14. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial // JAMA. - 2003. - № 289. - Р. 1799-804.
15. Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man // Diabetes Metab. - 2003. - № 29(4 Pt 2). - Р. 6S44-52.
16. Ibáñez L., Lopez-Bermejo A., Diaz M., Marcos M.V., de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity // J Pediatr. - 2010. - № 156(1). - Р. 98-102.e1.
17. Landin K., Tengborn L., Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors // J Intern Med. - 1991. - № 229(2). - Р. 181-7.
18. López Suárez A., Elvira González J., Beltrán Robles M., Alwakil M., Saucedo J.M., Bascuñana Quirell A., Barón Ramos M.A., Fernández Palacín F. [Prevalence of obesity, diabetes, hypertension, hypercholesterolemia and metabolic syndrome in over 50-year-olds in Sanlúcar de Barrameda, Spain] // Rev Esp Cardiol. - 2008. - № 61(11). - Р. 1150-8.
19. Marcucci R., Abbate R., Fedi S., Gori A.M., Brunelli T., Bruni V., Bucciantini S., Micheli S., Pepe G., Prisco D., Gensini G.F. Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels // Am J Clin Pathol. - 1999. - № 111(6). - Р. 769-72.
20. Poehlman E.T., Toth M.J., Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study // Ann Intern Med. - 1995. - № 123(9). - Р. 673-5.
21. Ragab A., Abousamra N.K., Higazy A., Saleh O. Relationship between insulin resistance and some coagulation and fibrinolytic parameters in patients with metabolic syndrome // Lab Hematol. - 2008. - № 14(1). - Р. 1-6.
22. Rissanen P., Vahtera E., Krusius T., Uusitupa M., Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women // Int J Obes Relat Metab Disord. - 2001. - № 25(2). - Р. 212-8.
23. Stachowiak G., Polac I., Wozniak P., Pertynski T., Pawlowicz P., Jedrzejczyk S., Makula A. [Evaluation of coagulation and fibrinolysis systems in women at peri- and postmenopausal age qualified for hormone replacement therapy] // Ginekol Pol. -2000. - № 71(9). - Р. 1110-4.
24. Trost S., Pratley R., Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type II diabetes // Curr Diab Rep. - 2006. - № 6. - Р. 47-54.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - № 352(9131). - Р. 854-65.
26. Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., Whincup P.H. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men // Atherosclerosis. - 2005. - № 181(1). - Р. 101-8.
27. Wulffelé M.G, Kooy A., de Zeeuw D., Stehouwer C.D., Gansevoort R.T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review // J Intern Med. - 2004. - № 256(1). - Р. 1-14.
28. Zamboni M., Armellini F., Milani M.P., De Marchi M., Todesco T., Robbi R., Bergamo-Andreis I.A., Bosello O. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships // Int J Obes Relat Metab Disord. - 1992. - № 16(7). - Р. 495-504.
Review
For citations:
, , Vliyanie metformina na provospalitel'nyei prokoagulyantnye narusheniya u patsientokv postmenopauze s metabolicheskim sindromom. Obesity and metabolism. 2011;8(2):36-46. (In Russ.) https://doi.org/10.14341/2071-8713-4951
Views:
631
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
